Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group.

health technology assessment precision medicine and diagnostics value frameworks

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
05 2020
Historique:
received: 18 07 2019
revised: 18 11 2019
accepted: 25 11 2019
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 29 8 2020
Statut: ppublish

Résumé

Precision medicine is a dynamic area embracing a diverse and increasing type of approaches that allow the targeting of new medicines, screening programs or preventive healthcare strategies, which include the use of biologic markers or complex tests driven by algorithms also potentially taking account of patient preferences. The International Society for Pharmacoeconomics and Outcome Research expanded its current work around precision medicine to (1) describe the evolving paradigm of precision medicine with examples of current and evolving applications, (2) describe key stakeholders perspectives on the value of precision medicine in their respective domains, and (3) define the core factors that should be considered in a value assessment framework for precision medicine. With the ultimate goal of improving health of well-defined patient groups, precision medicine will affect all stakeholders in the healthcare system at multiple levels spanning the individual perspective to the societal perspective. For an efficient, timely and practical precision medicine value assessment framework, it will be important to address these multiple perspectives through building consensus among the stakeholders for robust procedures and measures of value aspects, including performance of precision mechanism; aligned reimbursement processes of precision mechanism and subsequent treatment; transparent expectations for evidence requirements and study designs adequately matched to the intended use of the precision mechanism and to the smaller target patient populations; recognizing the potential range of value-generation such as ruling-in and ruling-out decisions.

Identifiants

pubmed: 32389217
pii: S1098-3015(20)30092-9
doi: 10.1016/j.jval.2019.11.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

529-539

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Eric Faulkner (E)

Evidera, Bethesda, MD, USA; University of North Carolina at Chapel Hill, Chapel Hill, NC; National Association of Managed Care Physicians, Glen Allen, VA, USA. Electronic address: eric.faulkner@evidera.com.

Anke-Peggy Holtorf (AP)

Health Outcomes Strategies, Basel, Switzerland.

Surrey Walton (S)

University of Illinois at Chicago, Chicago, IL, USA; Second City Outcomes Research, LLC, Chicago, IL, USA.

Christine Y Liu (CY)

Methodist Health System, Richardson, TX, USA.

Hwee Lin (H)

National University of Singapore, Singapore.

Eman Biltaj (E)

University of Utah, Salt Lake City, UT, USA.

Diana Brixner (D)

University of Utah, Salt Lake City, UT, USA.

Charles Barr (C)

Strategic Consulting, San Francisco, CA, USA.

Jennifer Oberg (J)

Columbia University, New York, NY, USA.

Gurmit Shandhu (G)

Gurmit Shandhu Consulting GMBH, Basel, Switzerland.

Uwe Siebert (U)

University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria; Harvard School of Public Health and Harvard Medical School, Boston, MA, USA; ONCOTYROL Center for Personalized Cancer Medicine, Innsbruck, Austria.

Susan R Snyder (SR)

Georgia State University, Atlanta, GA, USA.

Simran Tiwana (S)

Amgen, Thousand Oaks, CA, USA.

John Watkins (J)

Premera Blue Cross, Mountlake Terrace, WA, USA.

Maarten J IJzerman (MJ)

University of Melbourne Centre for Cancer Research, Parkville, Australia.

Katherine Payne (K)

The University of Manchester, Manchester, England, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH